SA

Shyam Anandapadmanabhan Nair

Active Director Director DIN 08476361
DIN 08476361 First appointment Feb 2020 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Shyam Anandapadmanabhan Nair

Data last updated:

Shyam Anandapadmanabhan Nair is a Director at Simaios Healthcare Private Limited (since 2020). The company operates in Pharma.

DIN 08476361
Primary Designation Director
Industry Pharma
First Appointment 03 Feb 2020
Oldest Company Age 7 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Simaios Healthcare Private Limited U24100MH2019PTC326485
Director03 Feb 20202019Active

Board colleagues of Shyam Anandapadmanabhan Nair

Directorship timeline

Open interactive timeline →
Simaios Healthcare Private Limited
Premium access

Shareholding and investment profile for Shyam Anandapadmanabhan Nair

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shyam Anandapadmanabhan Nair

Shyam Anandapadmanabhan Nair currently holds 1 directorship: Simaios Healthcare Private Limited (Director, since 03 Feb 2020).

Shyam Anandapadmanabhan Nair was first appointed on 03 Feb 2020 as Director at Simaios Healthcare Private Limited.

The current boards of Shyam Anandapadmanabhan Nair's companies include Harikumar Balakrishnapillai (Simaios Healthcare Private Limited), Prasobh Ramachandranpillai Kumar (Simaios Healthcare Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available